Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | TEK | Q02763 | 2/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1244985 | 0.91 | L3MBTL1 (0.57) | L3MBTL1PSDCREBBPSMN1; SMN2NPC1 | |
| SCHEMBL20658807 | 0.87 | L3MBTL1 (0.55) | L3MBTL1PSDCREBBPSMN1; SMN2HDAC2 | |
| SCHEMBL17591714 | 0.83 | HSD17B10 (0.49) | L3MBTL1PSDSMN1; SMN2LMNAMAPT | |
| SCHEMBL4769322 | 0.81 | SMN1; SMN2 (0.51) | L3MBTL1PSDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL30755398 | 0.81 | LMNA (0.58) | PSDCREBBPSMN1; SMN2NPC1RAB9A | |
| SCHEMBL20658827 | 0.81 | HSD17B10 (0.67) | L3MBTL1PSDSMN1; SMN2LMNAMAPT | |
| SCHEMBL18586165 | 0.79 | VDR (0.48) | PSDRAB9AHSP90AB1 | |
| SCHEMBL17094867 | 0.78 | L3MBTL1 (0.50) | L3MBTL1NPC1RAB9AMAPTHSP90AB1 | |
| SCHEMBL18235823 | 0.78 | KMT2A (0.62) | L3MBTL1PSDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL17095073 | 0.77 | CYP3A4 (0.60) | PSDLMNAMAPTHDAC2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| WO-2017040449-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | L3MBTL1 4794/4885PSD 3739/4885CREBBP 1663/4885 |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | L3MBTL1 4794/4885PSD 3739/4885CREBBP 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.